Form 4: Apogee CMO Granted 83,690 Stock Options

Apogee Therapeutics' Chief Medical Officer, Carl Dambkowski, was granted 83,690 stock options with an exercise price of $75.78.

Summary

• Carl Dambkowski, Chief Medical Officer of Apogee Therapeutics, Inc. (APGE), was granted stock options.
• The grant occurred on January 2, 2026.
• The options allow the purchase of 83,690 shares of common stock.
• The exercise price for these options is $75.78 per share.
• The options will vest in 48 equal monthly installments over a four-year period from the grant date, contingent on Dambkowski's continued service.
• The options expire on January 2, 2036.

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally a positive signal, indicating management retention and alignment of interests, though it doesn't reflect operational performance.

Positives

• The grant of stock options to the Chief Medical Officer aligns management incentives with shareholder interests.
• The vesting schedule encourages long-term commitment and retention of key executive talent.

Risks

• The value of the options is dependent on the future stock price of Apogee Therapeutics, Inc. exceeding the exercise price of $75.78.
• Vesting is subject to continued service, meaning the options could be forfeited if employment ceases.

Future Outlook

The stock option grant incentivizes the Chief Medical Officer to contribute to the company's long-term growth and share price appreciation over the four-year vesting period and ten-year option term.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology and pharmaceutical industries, used to attract, retain, and motivate key scientific and medical talent by aligning their financial interests with company performance.

Comparison to Industry Standards

• The grant of stock options to a Chief Medical Officer is a standard practice in the biotech industry for executive compensation, comparable to practices at companies like Moderna or BioNTech, which frequently use equity to incentivize leadership.
• The four-year vesting schedule is typical for executive equity grants, similar to those observed at peer companies such as Vertex Pharmaceuticals or Regeneron Pharmaceuticals, ensuring long-term commitment.
• The exercise price being set at the market price on the grant date is standard for incentive stock options, aligning with best practices for performance-based compensation.

Stakeholder Impact

• Shareholders: Potential dilution if options are exercised, but also potential for increased shareholder value if the options incentivize strong performance.
• Employees: May signal confidence in the company's future and serve as a model for other employee incentive programs.

Next Steps

• The options will vest monthly over the next four years, subject to continued service.
• The Chief Medical Officer may choose to exercise these options at any point after vesting and before the expiration date.

Key Dates

Recommendation

This Form 4 reports a routine executive compensation event (stock option grant) which aligns management incentives with shareholder interests. It does not provide new information on operational performance, financial results, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as it maintains the current stance without new fundamental data.

Keywords

Apogee Therapeutics, APGE, Stock Options, CMO, Carl Dambkowski, Executive Compensation, Form 4, Insider Transaction, Equity Grant